Komori
Earnings4586Medrx Co.,Ltd.Pharmaceuticals

Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

For the interim period of the fiscal year ending December 2026, revenue decreased 37.7% year on year to ¥11 million. Operating, ordinary and net losses narrowed from the same period of the previous year, mainly due to lower selling, general and administrative expenses, but the company remained in the red.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
37.7
% (year-on-year decline in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAP
Net Sales11million yenYear on year -37.7%Progress 2.9%
Operating profit-544million yen
Ordinary income-554million yen
Net income attributable to owners of the parent-551million yen

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥(9.27)
Financial position at period-end
Total assets1,742million yen
of which net assets 1,592 million yenEquity ratio 88.3%vs. prior year-end -3.9pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-661,446
Investment-3,198
Financials+47,236
Net change-617,408

Stacked from zero: upward is an increase in cash, downward a decrease (in thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period1,143,322 thousand yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales385 million yen (YoY +300.7%)
Operating profit-1,206 million yen
Ordinary income-1,197 million yen
Net income-1,202 million yen
Revision to Earnings ForecastNot disclosed → Net Sales 385 / Operating profit -1,206 / Ordinary income -1,197 / Net income -1,202
Annual Dividend Forecast0 yen and sen → 0 yen and sen(0.0%)
Factors Behind Changes in Business Performance

Revenue was ¥11 million (¥18 million in the same period of the previous year), while selling, general and administrative expenses were ¥553 million (¥627 million in the same period of the previous year). The company recorded ¥2 million in non-operating income, ¥12 million in non-operating expenses and ¥9 million in extraordinary income from the reversal of stock acquisition rights.

Disclosure regarding the going concern assumption

No matters requiring disclosure were identified in the notes on the going concern assumption. However, the company stated that the continuation of operating losses constitutes a situation that raises significant doubt about the going concern assumption, but that funding has been secured and management recognizes that there is no material uncertainty.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares 9,979 thousand yen / Extraordinary loss Not disclosed
Depreciation and amortization5,113 thousand yen
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End60,271,100
Treasury Shares at Period-End2
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 January 2026–30 June 2026
Net Sales11 million yen (YoY -37.7%)
Operating profit-544 million yen
Ordinary income-554 million yen
Profit attributable to owners of the parent-551 million yen
Net income per share¥(9.27)
Equity ratioEnd of the current fiscal period 88.3 / End of previous period 92.2
Total assets1,742 million yen
Net assets1,592 million yen
Cash flows from operating activities-661,446 thousand yen
Cash flows from investing activities-3,198 thousand yen
Cash flows from financing activities47,236 thousand yen
Cash and cash equivalents at end of period1,143,322 thousand yen
Full-year earnings forecastNet Sales 385 million yen (YoY +300.7%) / Operating profit -1,206 million yen / Ordinary income -1,197 million yen / Net income -1,202 million yen
Revision to Earnings ForecastNot disclosed → Net Sales 385 / Operating profit -1,206 / Ordinary income -1,197 / Net income -1,202
Annual Dividend Forecast0 yen and sen → 0 yen and sen(0.0%)
Depreciation and amortization5,113 thousand yen
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares 9,979 thousand yen / Extraordinary loss Not disclosed
Disclosure regarding the going concern assumptionNo matters requiring disclosure were identified in the notes on the going concern assumption. However, the company stated that the continuation of operating losses constitutes a situation that raises significant doubt about the going concern assumption, but that funding has been secured and management recognizes that there is no material uncertainty.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End60,271,100
Treasury Shares at Period-End2
Factors Behind Changes in Business PerformanceRevenue was ¥11 million (¥18 million in the same period of the previous year), while selling, general and administrative expenses were ¥553 million (¥627 million in the same period of the previous year). The company recorded ¥2 million in non-operating income, ¥12 million in non-operating expenses and ¥9 million in extraordinary income from the reversal of stock acquisition rights.
Items this document does not state (9)
Operating MarginPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Selling, general and administrative expenses, including research and development expenses and other expenses, decreased to ¥553 million from ¥627 million in the same period of the previous year. The company recorded ¥2 million in non-operating income, ¥12 million in non-operating expenses and ¥9 million in extraordinary income from the reversal of stock acquisition rights. No specific reason for the decrease in revenue was disclosed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated) | Medrx Co.,Ltd. (4586) timely disclosure | Komori